A detailed history of Simplex Trading, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 129,860 shares of RCUS stock, worth $2 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
129,860
Previous 9,723 1235.6%
Holding current value
$2 Million
Previous $183,000 980.33%
% of portfolio
0.07%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$14.59 - $18.48 $1.75 Million - $2.22 Million
120,137 Added 1235.6%
129,860 $1.98 Million
Q1 2024

Apr 25, 2024

SELL
$14.83 - $20.18 $1.15 Million - $1.56 Million
-77,361 Reduced 88.83%
9,723 $183,000
Q4 2023

Feb 02, 2024

BUY
$13.43 - $19.63 $30,768 - $44,972
2,291 Added 2.7%
87,084 $1.66 Million
Q3 2023

Nov 01, 2023

SELL
$17.62 - $23.54 $700,359 - $935,667
-39,748 Reduced 31.92%
84,793 $1.52 Million
Q2 2023

Aug 04, 2023

BUY
$16.97 - $22.03 $1.97 Million - $2.55 Million
115,943 Added 1348.49%
124,541 $2.53 Million
Q1 2023

Apr 27, 2023

BUY
$15.96 - $23.15 $137,224 - $199,043
8,598 New
8,598 $156,000
Q2 2022

Aug 03, 2022

SELL
$17.23 - $37.73 $3,359 - $7,357
-195 Closed
0 $0
Q1 2022

May 02, 2022

SELL
$28.92 - $41.83 $579,614 - $838,356
-20,042 Reduced 99.04%
195 $6,000
Q3 2021

Oct 28, 2021

BUY
$26.93 - $37.68 $2,693 - $3,768
100 Added 0.5%
20,237 $557,000
Q2 2021

Aug 12, 2021

BUY
$22.75 - $35.77 $458,116 - $720,300
20,137 New
20,137 $552,000
Q1 2021

Apr 26, 2021

SELL
$26.16 - $41.39 $647,957 - $1.03 Million
-24,769 Closed
0 $0
Q4 2020

Feb 02, 2021

BUY
$17.0 - $32.36 $421,073 - $801,524
24,769 New
24,769 $643,000
Q4 2019

Feb 05, 2020

SELL
$7.33 - $10.79 $417 - $615
-57 Closed
0 $0
Q3 2019

Oct 15, 2019

BUY
$6.44 - $10.18 $367 - $580
57 New
57 $0

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.11B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.